Evotec Slashes 2026 Revenue Guidance by ~20%, EBITDA Swings to Deep Loss
EVO is trading near its 52-week low of $2.308 (1.4% above the low) on elevated volume (2.0× avg).
Summary
Evotec just pre-announced a brutal H1 and slashed full-year guidance. Preliminary H1 revenue came in at ~€300.1M with adjusted EBITDA of -€42.7M. The company now expects FY2026 revenue of €570-610M, down sharply from prior guidance of €700-780M, and adjusted EBITDA of -€70 to -105M versus a prior range of €0-40M. This follows a string of negative signals — a CFO departure in April, weak Q1 results in May, and an executive share sale in June. The magnitude of the guidance cut, especially the swing to a significant EBITDA loss, suggests deeper operational challenges than previously disclosed. Liquidity of €465.6M provides some cushion, but the cash burn trajectory is now a central concern. Full Q2 results are due August 13.
At the time of this announcement, EVO was trading at $2.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $2.31 to $4.42. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: PR Newswire.